Details of the Drug

General Information of Drug (ID: DMMOFHT)

Drug Name
Pirprofen
Synonyms
Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei
Indication
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [1]
ATC Code
M01AE08: Pirprofen
M01AE: Propionic acid derivatives
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 251.71
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.4 micromolar/kg/day [3]
Chemical Identifiers
Formula
C13H14ClNO2
IUPAC Name
2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
Canonical SMILES
CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
InChI
InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
InChIKey
PIDSZXPFGCURGN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
35935
ChEBI ID
CHEMBL135028
CAS Number
31793-07-4
UNII
T7KN291890
DrugBank ID
DB13722
TTD ID
D0S9ET
INTEDE ID
DR1304
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [5]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Gene/Protein Processing [5]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Gene/Protein Processing [5]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Gene/Protein Processing [5]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Gene/Protein Processing [5]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
5 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.